Ionis Pharmaceuticals, Inc. Announces The Journal Of The American Medical Association Published Results From The Phase 3 NEURO-TTRansform Study Of Eplontersen, An Investigational Treatment For Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that The Journal of the American Medical Association published positive results from the Phase 3 NEURO-TTRansform study of eplontersen, a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The study showed that eplontersen halted disease progression and improved quality of life at 35-, 66- and 85-week analyses. Ionis and AstraZeneca are seeking regulatory approval for eplontersen in the U.S. and other parts of the world. The FDA granted a PDUFA action date of Dec. 22, 2023.
September 28, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals' eplontersen showed positive results in a Phase 3 study, halting disease progression and improving quality of life. The company is seeking regulatory approval for the drug.
The positive results from the Phase 3 study of eplontersen are a significant milestone for Ionis Pharmaceuticals. This could potentially lead to regulatory approval and commercialization of the drug, which would have a positive impact on the company's revenues and stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100